首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1410096

腫瘤學人工智慧市場：2023 年至 2028 年預測

AI in Oncology Market - Forecasts from 2023 to 2028

出版日期: 2023年12月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計在預測期內，腫瘤學市場的人工智慧將以 35.17% 的複合年成長率成長。

在人工智慧 (AI) 的幫助下，腫瘤學領域正在取得巨大突破。人工智慧提供的多重好處正在推動人工智慧在癌症研究中的日益採用，並推動人工智慧在腫瘤學市場的發展。此外，癌症患者盛行率的增加、癌症風險的增加以及人口老化也有望推動腫瘤學領域的人工智慧市場。此外，市場參與者針對人工智慧整合和產品推出的研究計劃和資金正在進一步推動腫瘤市場的人工智慧。

人工智慧在腫瘤學中的好處

將人工智慧涵蓋癌症研究的各種好處是腫瘤學市場人工智慧的關鍵成長要素。例如，乳房 X 光檢查、電腦斷層掃描和 MRI 影像可以透過人工智慧演算法進行分析，以尋找癌症的早期徵兆。這些演算法經常發現人類放射科醫生可能錯過的模式和異常，從而實現更早的診斷和更好的結果。人工智慧可以透過分析患者資訊、醫療記錄和臨床指南並制定治療方法來協助腫瘤學家。 AI演算法可以綜合考慮腫瘤大小、位置、患者特徵等多種因素，提案最佳治療策略。此外，人工智慧模型可以分析臨床記錄和治療史等患者資料，以預測疾病發作、治療反應和整體預後。

癌症患者增加

癌症患者數量的增加、治療和早期檢測的緊迫性預計將推動腫瘤市場的人工智慧發展。例如，根據世界衛生組織的數據，2020 年約有 1,000 萬人（約六分之一的死亡人數）死於癌症，使其成為全球主要死亡原因。據世界癌症研究基金會稱，2020年將有超過1800萬新癌症患者被診斷出來，其中男性930萬，女性880萬。此外，根據世界衛生組織的說法，如果及早發現並給予適當的治療，許多癌症是可以治癒的。病例的增加表明人工智慧在腫瘤學領域的應用增加，因為人工智慧可以幫助早期發現並改善治療結果。

加大研究及資金籌措力度

由於支持腫瘤學人工智慧市場的資助研究，人工智慧的使用已經有了一些前景。例如，NCI 的校內研究計畫正在利用人工智慧功能來增強前列腺癌和子宮頸癌的癌症篩檢。 Cancer Moonshot 與能源部 (DOE) 合作，資助兩項重要舉措，當該計劃於 2022 年恢復時，這些計劃將利用超級計算技能和能力進行癌症研究。此外，作為癌症登月計畫的一部分，NCI 在五年內（2022-2027 年）向四個學術研究機構撥款 2,300 萬美元。每個中心將重點放在廣泛的與癌症相關的遠端醫療研究問題，這些問題將作為其研究的框架。

人口老化

年齡越大，與癌症共存就越困難。老年人的許多癌症被發現較晚，因為癌症的早期症狀可能與全身疼痛或其他與老齡化相關的疾病混淆。根據世界衛生組織預測，2020年，60歲及以上人口將超過5歲以下人口，2015年至2050年間，全球60歲及以上人口比例將從12%增至22%。據美國癌症協會稱，2019 年約有 140,690 名癌症患者被診斷出，103,250 名美國老年人死於該疾病。不斷成長的老齡化人口預計將推動腫瘤學領域的人工智慧市場發展，因為人工智慧可以分析影像並有助於早期發現癌症。

市場抑制因素

預計很少有因素會限制腫瘤市場的人工智慧。例如，將人工智慧應用於癌症需要在基礎設施、運算能力和技術知識方面進行大量投資。這些成本可能會阻礙普及，特別是在資源有限的醫療機構。此外，人工智慧模型通常充當“黑盒子”，使其決策流程難以理解和分析。需要了解人工智慧生成建議背後推理的醫療保健專業人員和患者可能會擔心這種缺乏可解釋性。

北美地區預計將大幅成長

預計在預測期內，北美地區將佔據腫瘤學人工智慧市場的重要佔有率。造成這一佔有率的因素包括癌症患者的增加、人口老化、醫療保健的改善以及人工智慧的引入。例如，根據 CDC 的數據，癌症是美國第二大死因，2021 年約有 190 萬例癌症。根據美國癌症協會的數據，美國成長最快的年齡層是 85 歲及以上的成年人。此外，Azra AI、IBM 和英特爾公司等主要市場參與者的存在預計將透過技術進步進一步推動腫瘤學市場的人工智慧。

主要市場參與者

西門子 Healthineers 是一家國際醫療技術提供商，專注於醫療保健行業的產品、服務和解決方案。我們提供廣泛的影像系統，包括 CT、MRI、分子影像、X 光、超音波和血管造影術。 Digital Diagnostics Inc. 是一家領先的人工智慧診斷公司，其使命是透過科技應用改善醫療保健。該公司開發的 Dermspot 是一種人工智慧驅動的演算法，可以檢測黑色素瘤、鱗狀細胞癌和基底細胞癌等皮膚癌。

新興市場的主要發展

2023 年 6 月，Tempus 推出了 Tempus One，這是一款語音和文字助手，可幫助腫瘤內科醫生輕鬆存取患者資料。 2023 年 5 月，Belong.Life 宣布推出對話式 AI 腫瘤學導師「Dave」。它是同類產品中的第一個，旨在吸引和教育癌症患者的臨床旅程。截至 2023 年 5 月，Dave 對 10,000 名癌症患者進行了測試。 2023年1月，Massive Bio宣布將於2023年上半年推出一款新的人工智慧藥物配對工具。 2022 年 12 月，Digistain 宣布推出突破性的 AI 乳癌診斷工具，以協助降低成本。該工具旨在以超過 99% 的準確率進行診斷，並減少等待時間和化療的使用。

The discipline of oncology has seen tremendous breakthroughs through the help of artificial intelligence (AI). Multiple advantages offered by the AI are driving the increased adoption of it in cancer studies thereby propelling the AI in oncology market. Moreover, the growing prevalence of cancer cases coupled with an aging population and their higher risk of cancer is also expected to boost the AI in oncology market. Additionally, the research initiatives and funds for AI incorporation and product launches by market players are further aiding the AI in oncology market.

Advantages of AI in Oncology

The various advantages of incorporating AI in cancer studies are a major growth driver of AI in oncology market. For example, mammograms, CT scans, and MRI images can be analyzed by AI algorithms to look for early indications of cancer. These algorithms frequently find patterns and anomalies that human radiologists might overlook, enabling earlier diagnosis and better results. AI can help oncologists by analyzing patient information, medical records, and clinical guidelines to help them create treatment regimens. AI algorithms can suggest the best course of treatment by taking into account many elements like the tumor's size, location, and patient characteristics. Moreover, to forecast illness development, treatment response, and overall prognosis, AI models can analyze patient data, including clinical records and treatment history.

Growing Prevalence of Cancer Cases

The rising cases of cancer and the urgency of treatment and early detection are expected to boost the AI in oncology market. For instance, roughly 10 million deaths, or roughly one in six deaths, were caused by cancer in 2020, making it the top cause of death globally according to the WHO. According to World Cancer Research Fund International, there were more than 18 million new cancer cases in 2020 with 9.3 million in men and 8.8 million in women. Moreover, WHO says that many cancers are curable if caught early and treated appropriately. As AI can help in early detection and improved outcomes, therefore, rising cases indicate more adoption of AI in oncology.

Increased Research and Funding Initiatives

There are already several prospects for the usage of AI as a result of funded research that is aiding the AI in oncology market. For example, the capabilities of AI are being used by the NCI's intramural research program to enhance cancer screening for prostate and cervical cancer. In collaboration with the Department of Energy (DOE), the Cancer Moonshot is financing two significant initiatives that make use of supercomputing skills and capacity for cancer research with the relaunch of the program in 2022. Moreover, in the course of five years (2022-2027), the NCI gave four university research organizations $23 million as part of the Cancer Moonshot program. Each center will concentrate on a broad telehealth research subject related to cancer that will serve as the framework for their investigations.

Aging Population

Living with cancer becomes more challenging as people get older. As early cancer symptoms can be confused with common pain or other ailments related to ageing, many cancers in older persons are discovered at a later stage. According to the WHO, in 2020, there were more persons over the age of 60 than under five-year-olds and the percentage of people over 60 in the world will increase from 12% to 22% between 2015 and 2050. Around 140,690 cancer cases were diagnosed in 2019, while 103,250 elderly Americans lost their lives to the disease as per the American Cancer Society. As AI can analyze images and help in the early detection of cancer, therefore, rising aging population is contemplated to boost the AI in oncology market.

Restraints in the Market

Few factors are expected to limit the AI in oncology market. For example, a large investment in infrastructure, computer capacity, and technological know-how is necessary to implement AI in cancer. Widespread adoption may be hampered by these expenses, particularly in healthcare settings with limited resources. Moreover, It can be difficult to comprehend and analyze the decision-making processes of AI models since they frequently function as "black boxes." Healthcare professionals and patients who need to comprehend the reasoning behind AI-generated recommendations may become concerned about this lack of interpretability.

North America is Expected to Grow Significantly

The North American region is expected to hold a significant share of AI in oncology market during the forecasted period. Various factors attributed to such a share are rising cancer cases, an aging population, a strong healthcare presence, and the adoption of AI. For example, cancer is the second-most leading cause of death in the US as per the CDC with around 1.9 million cases in 2021. The fastest-growing age group in the US is adults over the age of 85 as per the American Cancer Society. Moreover, the presence of major market players such as Azra AI, IBM, and Intel Corporation are further expected to propel the AI in oncology market through technological advancements.

Major Market Players

An international provider of medical technology, Siemens Healthineers focuses on products, services, and solutions for the healthcare industry. A wide range of imaging systems is available from Siemens Healthineers, including systems for computed tomography (CT), magnetic resonance imaging (MRI), molecular imaging, X-ray, ultrasound, and angiography.
Digital Diagnostics Inc. is one of the advanced AI diagnostics companies with a mission of improving healthcare through the application of technology. Dermspot developed by the company is an AI-powered algorithm that detects melanoma, squamous cell carcinoma, and basal cell carcinoma of skin cancer.

Key Market Developments

In June 2023, for oncologists to have simpler access to patient data, Tempus introduced Tempus One, a voice-and-text assistant.
In May 2023, Belong.Life launched a conversational AI oncology mentor dubbed Dave. It is the first of its kind, developed to engage and educate cancer patients on their clinical journey. Dave was tested on 10,000 people with cancer up to May 2023.
In January 2023, Massive Bio announced the introduction of a new AI-powered medication matching tool in the first half of 2023 that will let doctors proactively find additional cancer therapy alternatives for their patients.
In December 2022, Digistain launched a new revolutionary AI breast cancer diagnostic tool that will help in cost saving. It is designed to reduce waiting times and the use of chemotherapy with more than 99% accuracy in diagnostics.

Segmentation:

By Component Type

Software Solutions
Hardware
Services

By Cancer Type

Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others

By Treatment Type

Chemotherapy
Radiotherapy
Immunotherapy
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. AI IN ONCOLOGY MARKET, BY COMPONENT TYPE

5.1. Introduction
5.2. Software Solutions
5.3. Hardware
5.4. Services

6. AI IN ONCOLOGY MARKET, BY CANCER TYPE

6.1. Introduction
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Prostate Cancer
6.5. Colorectal Cancer
6.6. Brain Tumor
6.7. Others

7. AI IN ONCOLOGY MARKET, BY TREATMENT TYPE

7.1. Introduction
7.2. Chemotherapy
7.3. Radiotherapy
7.4. Immunotherapy
7.5. Others

8. AI IN ONCOLOGY MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others